A team
close to you

Our team combines expertise, flexibility and proximity to meet your needs with professionalism. Our facilities guarantee quality and compliance of our analytical methods in each of our 3 fields of activity (preclinical, clinical and quality control testing).

Meet our team

Serge Braun

Serge Braun, PharmD, PhD started his career with traineeships in France and in USC (Los Angeles). Following a first 10-year period in public institutions he joined for an additional 10 years Transgene (Strasbourg, France) where he became Vice-president Research and developed his career in the field of gene therapy of genetic diseases and of immunotherapy of cancer. He was co-founder of Neurofit, a contract research organization specialized in preclinical testings of both the central and the peripheral nervous system. He was Vice-president of Alsace BioValley, the tri-national initiative, for the development of a major biotech cluster in Europe. He joined AFM-Telethon (the French Muscular dystrophy association) in 2006 as its Chief Scientific Officer. He is also scientific expert or member of the Scientific Board of different state organisms, non-profit associations, VC funds, biotechs and bioclusters, and reviewer of major journals. Serge was appointed as president of GenoSafe in 2013.

Pharm.D./ Ph.D., President

Alain Lamproye

Alain Lamproye has an extensive experience in bioprocessing and site management of biotech sites. He has been appointed Chief Executive Officer of Genosafe in February 2025. He was previously acting as CEO of Yposkesi and member of the Executive Leadership Team of SK pharmteco. Prior, he served as Chairman of the BioPharma Business Unit of Novasep since 2012, overseeing the Biologics CDMO business and the chromatographic equipment business of Novasep, after having held the position of CEO of Novasep’s subsidiary dedicated to Gene Therapy (Henogen, Belgium)(sold later to Thermo Fisher in 2021). He has worked for 9 years in pharmaceutical operations at Merck Serono, where he held various managerial positions, including Site Director of the EMD Serono Tech Ops site at Billerica (USA). Prior to that experience, he worked as GMP Production Director at Eurogentec (Belgium) for 14 years. Alain Lamproye holds a Master of Sciences from the University of Liège (Belgium).

Chief Executive Officer

Diane Sévézen

Diane Sévézen joined GenoSafe in May 2024 as Quality Director and Qualified Person. She has successively held positions of Quality Manager and Quality Director of manufacturing sites and sites for marketing authorisation holder. Acting as qualifed person deputy and qualified person, she has worked in the scientific fields of production, quality control, clinical development and medical affairs. Diane obtained her pharmacist degree from the Paris XI University, France, and completed her training by obtaining a master of science (DESS) in drug control and production from the Paul Sabatier University in Toulouse, France.

Pharm.D./ Ph.D., Quality Director

Noëlle Couget

Noëlle is an experienced CFO acting in the biotech industry for the last 25 years. Graduated in finance, holder of the IFA diploma (Institut Français des Administrateurs), she is also specialist in French research tax credit.

Chief Financial Officer

Christophe Poquet

Christophe received his BSc and MSc from Ecole Normale Supérieure and Université Pierre et Marie Curie in Paris. He is also a graduate of AgroParisTech and NEOMA Business School (Masternova). Christophe started his career in technology transfer departements (CNRS Innovation and Institut Pasteur) before evolving in the biotechnology industry where gene therapy (Genethon) and drug discovery activities (CYTOO) are prominent. He has more than 15 years experience in Licensing / Business Development activities. Christophe joined GenoSafe in 2020.

Head of Business Development

Aurore Lacroix

Following an MSc in Neurobiology, Aurore obtained a Master in Regulatory Affairs at the Faculty of Pharmacy of Lille and a Master in Pharmaceutical Marketing at the Faculty of Pharmacy of Paris XI. She has over 8 years of experience in Regulatory Affairs. She worked 3 years in Toronto (Canada) where she obtained Certificates in Canadian and US laws and Good Manufacturing Practices (GMP) . She worked for a Biotechnology Company specialized in oncology products (antibodies coupled to a toxin) where she was responsible of Intellectual Property Department. Aurore joined Genosafe in November 2013 as Regulatory Affairs Officer.

Quality Assurance and Regulatory Affairs Manager

Laurence Jeanson-Leh

Holder of a Master degree in Pharmacology from the University of Nice Sophia-Antipolis, Laurence obtained her Ph.D. in Life and Health Sciences in 2004 at the Ecole Normale Supérieure of Cachan following her work on HIV replication. She then joined the R & D department of Genethon as a research fellow and led various projects on immune deficiencies and muscular dystrophies. Specialized in molecular biology, vectorology and gene therapy, Laurence joined Genosafe in 2014.

Ph.D., Study Director, Quality Control

Agnès de Lacroix

After studying Biochemistry at the Denis Diderot Paris VII University (Université Paris Cité) and completing internships at the Institut Pasteur, Agnès earned her PhD in “Genomes and Proteins” in 2008. She then conducted postdoctoral research focused on membrane fusion processes: either between viral envelopes and liposomes (at INRA and CNRS) using virus models such as Chikungunya, or within mitochondria in the context of Charcot-Marie-Tooth disease (at INSERM). In 2015, she left the academic world to set-up an electron microscopy service within a CRO, where she later held the position of Study Director for six years. Agnès joined GenoSafe in 2022.

Ph.D., Study Director, Quality Control

Jean-Brice Marteau

Following a Master degree in Clinical Pharmacology and Drug Metabolism at the Faculty of Pharmacy of Nancy, Jean-Brice obtained his Ph.D. in Genetic Epidemiology in 2005. He then worked as a research engineer in the field of chronic lymphocytic leukemia at the Institute of cellular and molecular radiation biology from the CEA’s Life Science Division and as a researcher and project manager in the cardiovascular domain at INSERM. He then worked for a CRO as a molecular biology group leader in charge of the development of viral safety testing. Jean-Brice joined Genosafe in 2013 as a group manager and study director.

Ph.D., Study Director, Quality Control

Sabrina Triffault

Holder of a Master’s degree in in-depth immunology from the Pasteur Institute in Paris, Sabrina obtained her Ph.D in basic immunology in 2007 at the University of Angers. During her different post-doctoral fellowships, she addressed multiple aspects of immunology: innate immune response, development of antitumor immunotherapies, and study of the immune response against gene therapy vectors during her last position. Sabrina joined GenoSafe in 2015.

Ph.D., Study Director, Preclinical and Clinical Testing

Sarra Seninet

Holder of a Master degree in Life Therapies and Technologies from the Paris XIII University, Sarra obtained her Ph.D in Molecular and Cellular Biology in 2018 at the Sorbonne Paris University following her work on Rheumatoid Arthritis physiopathology and role of immune cells. She then joined the R&D department of Pharnext as a Research Scientist and led various projects on rare genetic diseases and immune diseases and involvement of big data genomics in the identification of new therapeutic targets. Specialized in Cellular Biology, and Immunology, Sarra joined Genosafe in 2022.

Ph.D., Study Director, Preclinical and Clinical Testing

William Lostal

Holder of a Master’s degree in cell, gene and tissue biotherapies, William received his PhD degree in molecular biology in 2010 at the University of Evry-Val d’Essonne. His research field focuses mainly on the development of AAV gene therapy treatments for rare genetic muscle diseases, especially during a postdoctoral stay in Columbia, MO, USA, then by joining Généthon in 2013. His main expertise are molecular biology and the immune response related to AAV treatments. Willliam joined Genosafe in 2019.

Ph.D., Study Director, Preclinical and Clinical Testing

A new GMP facility coming soon

Stay tuned to discover our future Quality Control facility: 1,200 square meters of laboratories dedicated to the testing of advanced therapeutics under GMPs.